ATE306281T1 - Antivirales mittel in kombination mit strahlentherapie zur verwendung in der behandlung von krebs - Google Patents

Antivirales mittel in kombination mit strahlentherapie zur verwendung in der behandlung von krebs

Info

Publication number
ATE306281T1
ATE306281T1 AT99402748T AT99402748T ATE306281T1 AT E306281 T1 ATE306281 T1 AT E306281T1 AT 99402748 T AT99402748 T AT 99402748T AT 99402748 T AT99402748 T AT 99402748T AT E306281 T1 ATE306281 T1 AT E306281T1
Authority
AT
Austria
Prior art keywords
treatment
cancer
combination
antiviral agent
radiation therapy
Prior art date
Application number
AT99402748T
Other languages
English (en)
Inventor
Jean Bourhis
Bassam Abdulkarim
Eric Deutsch
Original Assignee
Roussy Inst Gustave
Univ Paris
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roussy Inst Gustave, Univ Paris filed Critical Roussy Inst Gustave
Application granted granted Critical
Publication of ATE306281T1 publication Critical patent/ATE306281T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT99402748T 1999-11-04 1999-11-04 Antivirales mittel in kombination mit strahlentherapie zur verwendung in der behandlung von krebs ATE306281T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99402748A EP1097720B1 (de) 1999-11-04 1999-11-04 Antivirales Mittel in Kombination mit Strahlentherapie zur Verwendung in der Behandlung von Krebs

Publications (1)

Publication Number Publication Date
ATE306281T1 true ATE306281T1 (de) 2005-10-15

Family

ID=8242168

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99402748T ATE306281T1 (de) 1999-11-04 1999-11-04 Antivirales mittel in kombination mit strahlentherapie zur verwendung in der behandlung von krebs

Country Status (7)

Country Link
US (2) US6723712B2 (de)
EP (2) EP1097720B1 (de)
AT (1) ATE306281T1 (de)
AU (1) AU2158601A (de)
DE (1) DE69927688T2 (de)
ES (1) ES2251168T3 (de)
WO (1) WO2001032215A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030158220A1 (en) * 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
US20050113324A1 (en) * 2003-01-15 2005-05-26 Bondarev Igor E. Modulation of line-1 reverse transcriptase
CA2811272C (en) 2003-04-08 2016-12-20 Progenics Pharmaceuticals, Inc. Pharmaceutical formulations containing methylnaltrexone
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8524731B2 (en) * 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
ES2714198T3 (es) * 2005-03-07 2019-05-27 Univ Chicago Uso de antagonistas opioideos para atenuar la proliferación y la migración de células endoteliales
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
US20060107365A1 (en) * 2006-01-31 2006-05-18 Pioneer Hi-Bred International, Inc. Soybean variety XB37U06
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
TW200817048A (en) * 2006-09-08 2008-04-16 Wyeth Corp Dry powder compound formulations and uses thereof
US20080171783A1 (en) * 2006-12-28 2008-07-17 Migenix Inc. Compositions and methods for treating hyperproliferative disease
PL2137191T3 (pl) * 2007-03-29 2016-12-30 Antagoniści obwodowego receptora opioidowego i ich zastosowania
JP2010522756A (ja) * 2007-03-29 2010-07-08 プロジェニックス ファーマシューティカルズ，インコーポレーテッド 結晶形およびその使用
EP2565195B1 (de) * 2007-03-29 2015-05-06 Wyeth LLC Peripherer Opioid-Rezeptor sowie Antagonisten und Verwendungen davon
AU2008349873B2 (en) 2008-02-06 2014-02-13 Progenics Pharmaceuticals, Inc. Preparation and use of (R),(R)-2,2'-bis-methylnaltrexone
CA2719134C (en) 2008-03-21 2015-06-30 The University Of Chicago Treatment with opioid antagonists and mtor inhibitors
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
EP2371369A1 (de) 2010-04-01 2011-10-05 Institut Gustave Roussy (IGR) EGFR-Inhibitor und antivirales Mittel zur gleichzeitigen, getrennten oder aufeinanderfolgenden Verwendung bei der Behandlung und/oder Vorbeugung und/oder Abschwächung von Krebs
WO2012006550A2 (en) * 2010-07-09 2012-01-12 Obetech Llc Methods and compositions for treatment of lipogenic virus related conditions

Also Published As

Publication number Publication date
EP1097720B1 (de) 2005-10-12
US20020193339A1 (en) 2002-12-19
WO2001032215A1 (en) 2001-05-10
EP1097720A1 (de) 2001-05-09
EP1237576A1 (de) 2002-09-11
US6723712B2 (en) 2004-04-20
ES2251168T3 (es) 2006-04-16
US20040192637A1 (en) 2004-09-30
AU2158601A (en) 2001-05-14
DE69927688T2 (de) 2006-07-06
DE69927688D1 (de) 2006-02-23

Similar Documents

Publication Publication Date Title
ATE306281T1 (de) Antivirales mittel in kombination mit strahlentherapie zur verwendung in der behandlung von krebs
AU2002351196A1 (en) Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
DE69942827D1 (de) Verwendung der epothilons zur behandlung der krebs
ATE414512T1 (de) Kombinationstherapie zur behandlung von krebs
NO20000752D0 (no) Metode for forhindring eller behandling av østrogen-avhengige sykdommer og forstyrrelser
ATE415962T1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
ATE375795T1 (de) Verwendung von et743 in kombinationstherapie mit dexamethason zur behandlung von krebs
ATE402713T1 (de) Genetisch manipulierte herpesviren zur behandlung von tumoren
SE9904377D0 (sv) Pharmaceutical combinations
MXPA04007443A (es) Nuevos compuestos de porfirina-platino solubles en agua con alta selectividad tumoral y su uso para el tratamiento de enfermedades tumorales benignas y malignas.
ATE397000T1 (de) Tetrahydropyridothiophenen zur verwendung in der behandlung von krebs
PT1206256E (pt) Terapia de combinacao utilizando pentafluorobenzenosulfonamida e compostos de platina
PT1092040E (pt) Metodos de inibicao helicobacter pylori
AU2003234342A8 (en) Ablated slam-dependent entry
DK0938900T3 (da) Midler til forebyggelse/behandling af stomatitis
PT1472375E (pt) Produtos génicos expressos diferencialmente em células cancerígenas da mama e seus métodos de utilização
NO20014228D0 (no) Radioaktiv cisplatin i behandling av cancer
DE50011084D1 (de) Verwendung von azolen zur prävention von strahlen-induziertem hautkrebs
ATE415165T1 (de) Kombinierte tumortherapie auf der basis von distamycin-acryloyl derivate und antimetabolische mitteln
DE60318561D1 (de) Kombinierte tumortherapie auf der basis von distamycin-acryloyl derivaten und radiotherapie
ATE94759T1 (de) Verwendung von dextransulfat, gegebenenfalls in kombination mit anti-androgenen mitteln zur behandlung des humanen protatakarzinoms.
ZA200408071B (en) Combination therapy for the treatment of cancer.
CY1115806T1 (el) Παραγωγα του κυκλικου eστερα uk-2a χρησιμα στην προληψη ή την αντιμετωπιση μυκητολογικων ασθενειων
DE60024450D1 (de) Modulierung der angiogenese durch verwendung von anti-angiogenischen angiotensin-7 und dafür kodierende polynukleotiden zur behandlung von tumoren
ATE338541T1 (de) Labdan-enthaltende arzneiformulierungen zur behandlung von tumoren oder leukämien

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties